Back to News
Market Impact: 0.15
Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Source: globenewswire.com
Healthcare & BiotechCorporate Guidance & Outlook
Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track to begin, with topline results expected in the second half of 2027. The update provides a development timeline but no clinical results or other trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook
- AI data center firm IREN delays Microsoft AI deliveries, plans $15 billion spending push
- Pale Fire Capital SE acquires $31.45m Coursera stock